NCT05331066 Understanding immunE-related toXicities by multifACeT Profiling
| NCT ID | NCT05331066 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Royal Marsden NHS Foundation Trust |
| Condition | Oncology |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2022-04-06 |
| Primary Completion | 2028-04-06 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
A prospective observational cohort study of patients undergoing CPI therapy in which translational research is the fundamental aspect of the study.
Eligibility Criteria
Inclusion Criteria: * Written informed consent * Age 18 years or older * Confirmed diagnosis of any form of solid malignancy with a clinical indication and appropriate treatment plan to commence immune checkpoint inhibitor therapy Exclusion Criteria: * Medical or psychological condition that would preclude informed consent * Planned participation in a drug trial receiving investigational agents * Subjects who have previously commenced immune checkpoint inhibitor therapy prior to study entry. * Subjects unable to comply with the study or sample schedule.